Zura Bio Limited (NASDAQ:ZURA) Receives $15.80 Average PT from Brokerages

Zura Bio Limited (NASDAQ:ZURA) has been given a consensus rating of “Buy” by the seven brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $15.80.

Several brokerages recently commented on ZURA. HC Wainwright reaffirmed a “neutral” rating and issued a $5.00 target price on shares of Zura Bio in a research note on Tuesday, December 24th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th.

Institutional Trading of Zura Bio

Several large investors have recently added to or reduced their stakes in ZURA. Charles Schwab Investment Management Inc. boosted its holdings in Zura Bio by 51.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 291,807 shares of the company’s stock valued at $1,185,000 after acquiring an additional 98,972 shares in the last quarter. Valence8 US LP bought a new stake in Zura Bio in the third quarter valued at $71,000. The Manufacturers Life Insurance Company bought a new stake in Zura Bio in the third quarter valued at $71,000. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in Zura Bio in the third quarter valued at $46,000. Finally, MetLife Investment Management LLC purchased a new position in Zura Bio during the third quarter valued at $111,000. Institutional investors own 61.14% of the company’s stock.

Zura Bio Stock Up 18.5 %

Shares of NASDAQ ZURA opened at $1.28 on Monday. Zura Bio has a 52 week low of $1.07 and a 52 week high of $6.35. The firm’s fifty day moving average is $1.60 and its 200 day moving average is $2.89.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.